Mental health care often splits into two disconnected tracks: therapy and medication management. Siggy, a New York-based startup, has raised $6 million in pre-seed funding to close that gap using AI-driven check-ins that keep clinicians informed between visits.

What You Need to Know

Siggy was founded by Jonathan Sabbagh, co-founder of Journey Clinical, and Edvard Engesæth, co-founder of Nurx. The company uses AI conversations to gather patient histories and daily check-ins, which licensed clinicians review before video appointments. Village Global led the round, with participation from investors who previously backed the founders' earlier ventures. The funding will be used to hire clinicians and engineers, develop the software and address regulatory requirements.

Two Founders With a History of Disrupting Care Delivery

Siggy brings together two entrepreneurs who have already built businesses that move treatment outside traditional doctor's offices. Jonathan Sabbagh co-founded Journey Clinical, which supports practices offering ketamine-assisted psychotherapy. Edvard Engesæth co-founded Nurx, a telehealth service for birth control and other healthcare needs.

Their combined experience spans both psychedelic-assisted therapy and direct-to-consumer telehealth, two areas that have faced regulatory scrutiny and operational complexity. Siggy's model appears to draw on both: it offers a direct-to-patient service while navigating the rules around prescribing controlled substances and mental health treatment.

How Siggy's AI-Powered Model Works

Patients begin by answering questions about their history through a free AI conversation. They then meet a licensed clinician by video, who reviews that information, makes a diagnosis and prescribes medication if appropriate. Between appointments, Siggy uses AI conversations and daily check-ins to gather information clinicians can review.

"AI helps maintain the conversation and organize what patients share, so clinicians have a richer picture of the person that they're treating," Engesæth said in an interview.

The company is addressing a problem Sabbagh encountered in mental healthcare: therapists and the clinicians prescribing medication often work separately. Patients may see a therapist weekly but have only a brief appointment every few months with their prescriber, leaving little time to discuss changes in symptoms or medication side effects.

Investor Confidence and the Road Ahead

Village Global led the financing, and several investors in the round previously backed one or both founders. They include Albert Wenger of Union Square Ventures, Mercury co-founder Immad Akhund and Cityblock Health co-founder Toyin Ajayi, through Coalition Operators. Other participants include PsyMed Ventures, Mystic Ventures and Gokul Rajaram.

The founders said they began building Siggy in late 2025. The round is the first outside funding for the company. They plan to use the capital to hire more clinicians and engineers, develop the software and work on regulatory requirements. Siggy recently began accepting paying patients ahead of its public launch and plans to test the service with paying patients before expanding further.

Why This Matters

Siggy's approach could reshape how mental health care is delivered by making the space between appointments more clinically useful. For patients, that means their prescriber may have a fuller picture of how they are responding to medication, potentially reducing trial-and-error prescribing. For clinicians, it offers a way to monitor progress without adding more scheduled visits.

The startup, however, enters a crowded telehealth market where companies like Cerebral and Talkiatry have faced scrutiny over prescribing practices and data privacy. Siggy's success will depend on whether its AI can reliably capture clinically relevant information without introducing errors or bias. The founders' track record may give investors confidence, but the regulatory and ethical challenges of AI in mental health remain significant.